Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific

Co-Development will provide pipeline for next generation pharmacology research of Rx drugs to further secure growth for Tetra Bio-Pharma Inc

OTTAWA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific.  This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties.  In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval.

MAKScientific is a recognized world leader in endocannabinoid research and drug development.  MAKScientific has developed a pipeline of small molecule drugs that target the cannabinoid receptors (CB1 and CB2) as well as other targets implicated in the endocannabinoid system. Under this agreement, MAKScientific will develop new molecules that will be screened by Tetra for potential efficacy in various indications including cancer, pain and inflammation as well as other potential targets of interest to Tetra.  

“This collaboration with MAKScientific provides significant opportunities for Panag Pharma Inc to expand the company’s research to derisk and advance novel lead drug compounds to the clinic. MAKScientific’s founder, Professor Alexandros Makriyannis, is a pioneer in drug development in the cannabinoid space and his ground-breaking work has been instrumental to our understanding of how drugs interact with and modulate the endocannabinoid system,” said Dr. Melanie Kelly, CSO Panag Pharma and Tetra.

"A successful Biopharmaceutical company requires a pipeline of patent protected molecules that can become its next generation therapeutics.  Patent protection is one of the most important aspects to safeguarding the company’s assets and its shareholders investments," commented Dr. Guy Chamberland, CEO and CRO of Tetra. 

Tetra is growing rapidly into a fully vertically integrated pharmaceutical company that through its established agreements and strategic partnership can take a new molecule, developed and patented by MAKScientific, and bring it all the way to commercialization.  Tetra can leverage this co-development agreement by using its current know-how: